Skip to main content
Recursion secures FDA agreement for Phase 3 trial
Image for illustrative purposes only. Not a real photo.

Recursion secures FDA agreement for Phase 3 trial

By

Key points

  • Recursion Pharmaceuticals reached agreement with the FDA on the design of a Phase 3 trial for REC-4881, an experimental treatment for familial adenomatous polyposis (FAP).
  • The trial will use composite event-free survival as its primary measure, including the removal of adenomas measuring 10 mm or larger.
  • The study is expected to begin in the second half of 2027, with approximately 200 adults expected to enrol, following positive Phase 2 TUPELO findings.

Recursion Pharmaceuticals (NASDAQ:RXRX) reached an agreement with the US Food and Drug Administration (FDA) on the design of a Phase 3 trial for REC-4881, an experimental treatment for familial adenomatous polyposis (FAP).

The trial's primary measure will be composite event-free survival, which tracks the time until a qualifying disease-related event, including the removal of an adenoma measuring 10 millimetres or larger in either the upper or lower gastrointestinal tract.

The study will enrol approximately 200 adults with FAP who have undergone removal of all or part of their colon, or removal of both the colon and rectum.

Secondary measures will include progression on the modified Spigelman scale, which assesses the severity of upper gastrointestinal polyposis, and changes in total polyp burden.

Recursion expects to begin the Phase 3 trial in the second half of 2027.

REC-4881 is an investigational oral MEK1/2 inhibitor that has received FDA Orphan Drug and Fast Track designations, with the company developing it for FAP, a rare inherited condition for which no pharmacological treatments are currently approved.

The Phase 2 TUPELO trial previously showed a 47% median reduction in total polyp burden after 12 weeks of treatment, with 85% of evaluable patients remaining below their baseline polyp burden 12 weeks after stopping treatment.


Frequently asked questions